Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.55 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.33 |
| ▸ | FAAH | O00519 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | PTGIR | P43119 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16617749 | 1.00 | CTSK (0.55) | CTSKMAP4K1ALOX5APFAAHKDM4E | |
| SCHEMBL16617751 | 0.94 | CTSK (0.48) | CTSKMAP4K1ALOX5APHTR2CPTGIR | |
| SCHEMBL16618096 | 0.94 | CTSK (0.48) | CTSKMAP4K1ALOX5APHTR2CPTGIR | |
| SCHEMBL16617504 | 0.91 | CTSK (0.54) | CTSKMAP4K1FAAHBACE1BACE2 | |
| SCHEMBL16617502 | 0.86 | CTSK (0.78) | CTSK | |
| SCHEMBL16617505 | 0.85 | CTSK (0.47) | CTSKMAP4K1DGAT1 | |
| SCHEMBL16618136 | 0.84 | CTSK (0.36) | CTSKALOX5APPTGIR | |
| SCHEMBL16617500 | 0.80 | CTSK (0.69) | CTSK | |
| SCHEMBL16617897 | 0.78 | CTSK (0.54) | CTSKALOX5APKDM4E | |
| SCHEMBL16617794 | 0.78 | CTSK (0.54) | CTSKALOX5APKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3055314-B1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-09-12 | — | — | EP | disclosed |
| US-9458181-B2 | Cathepsin cysteine protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150099719-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099719-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | CTSB, CTSS, CTSZ | CTSK 4/4885MAP4K1 2664/4885ALOX5AP 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.